Hims & Hers Health shares rose 9.63% premarket after backing FDA plans to ease peptide therapy restrictions. Health Secretary RFK Jr. said the FDA will review select peptides in July with potential removal from the high-risk list. The company sees new revenue opportunities in regulated peptide channels. BofA cut its price target to $21, citing 2026 EBITDA pressure as GLP-1 contribution declines.
